As of 2026-01-19, the Relative Valuation of 10X Genomics Inc (TXG) is (18.41) USD. This relative valuation is based on P/E multiples. With the latest stock price at 20.52 USD, the upside of 10X Genomics Inc based on Relative Valuation is -189.7%.
The range of the Relative Valuation is (17.73) - (18.59) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 29.4x - 31.7x | 30.6x |
| Forward P/E multiples | 29.4x - 30.8x | 30.4x |
| Fair Price | (17.73) - (18.59) | (18.41) |
| Upside | -186.4% - -190.6% | -189.7% |
| Date | P/E |
| 2026-01-16 | -34.03 |
| 2026-01-15 | -35.15 |
| 2026-01-14 | -34.69 |
| 2026-01-13 | -34.03 |
| 2026-01-12 | -32.83 |
| 2026-01-09 | -33.93 |
| 2026-01-08 | -31.99 |
| 2026-01-07 | -33.15 |
| 2026-01-06 | -32.02 |
| 2026-01-05 | -30.38 |
| 2026-01-02 | -27.56 |
| 2025-12-31 | -27.04 |
| 2025-12-30 | -27.01 |
| 2025-12-29 | -26.78 |
| 2025-12-26 | -27.34 |
| 2025-12-24 | -27.67 |
| 2025-12-23 | -27.36 |
| 2025-12-22 | -28.09 |
| 2025-12-19 | -26.61 |
| 2025-12-18 | -26.53 |
| 2025-12-17 | -26.12 |
| 2025-12-16 | -26.05 |
| 2025-12-15 | -26.13 |
| 2025-12-12 | -25.63 |
| 2025-12-11 | -27.43 |
| 2025-12-10 | -29.07 |
| 2025-12-09 | -29.58 |
| 2025-12-08 | -28.97 |
| 2025-12-05 | -29.47 |
| 2025-12-04 | -30.10 |
| 2025-12-03 | -29.63 |
| 2025-12-02 | -29.75 |
| 2025-12-01 | -29.98 |
| 2025-11-28 | -31.19 |
| 2025-11-26 | -31.09 |
| 2025-11-25 | -31.62 |
| 2025-11-24 | -33.38 |
| 2025-11-21 | -30.41 |
| 2025-11-20 | -27.29 |
| 2025-11-19 | -25.95 |
| 2025-11-18 | -25.80 |
| 2025-11-17 | -26.03 |
| 2025-11-14 | -26.35 |
| 2025-11-13 | -27.11 |
| 2025-11-12 | -27.67 |
| 2025-11-11 | -27.51 |
| 2025-11-10 | -28.32 |
| 2025-11-07 | -25.29 |
| 2025-11-06 | -21.56 |
| 2025-11-05 | -22.37 |